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Abstract 
Background: Bipolar disorder is a chronic illness with a 2-year recurrence rate of approximately 50% among individu-
als receiving treatment in the community. The aim of this 18-month, open-label, continuation study was to evaluate 
the long-term safety and effectiveness of lurasidone in patients who initially presented with a major depressive epi-
sode associated with bipolar disorder, and who had completed at least 6 months of initial treatment with lurasidone.
Methods: Patients with bipolar I depression were enrolled in one of three 6-week, double-blind, placebo-controlled 
trials (monotherapy with lurasidone, 1 study; adjunctive therapy with lurasidone; and lithium or valproate, 2 studies). 
Study completers were eligible for a 6-month, open-label extension study of lurasidone utilizing flexible daily doses 
of 20–120 mg; extension completers were then eligible for an additional 18 months of continuation treatment with 
flexible, once-daily doses of lurasidone in the range of 20–80 mg. Concomitant therapy with mood stabilizers was 
permitted throughout the open-label extension and continuation studies.
Results: A total of 1199 patients entered, and 941 (78.5%) completed initial, double-blind, acute treatment, of whom 
817/941 (86.8%) entered, and 559 (68.4%) completed the 6-month extension study; 122/559 patients (21.8%) entered 
the 18-month continuation study, of whom 19.7% of discontinued, including 6.6% due to adverse events and 1.6% 
due to insufficient efficacy. The mean dose of lurasidone during the 18-month continuation study was 61.8 mg/
day, and the modal dose was 60 mg/day. Mean change in weight, from acute baseline to 18-month continuation 
endpoint was +0.8 kg (completers, n = 55); median changes in cholesterol and triglycerides were −3.0 mg/dL and 
+26.0 mg/dL, respectively. Based on a Kaplan–Meier analysis, the probability of relapse during 18 months of continu-
ation treatment with lurasidone was estimated to be 18.3% in the monotherapy group and 29.1% in the adjunctive 
therapy group. Improvement in global illness severity was also maintained during 18 months of continuation therapy 
(CGI-S at continuation baseline, 2.1; 18-month completers, 1.7; LOCF-endpoint, 1.9).
Conclusions: Up to 2 years of treatment with lurasidone was safe and well tolerated in this bipolar disorder popula-
tion presenting with an index episode of depression. Improvement in depressive symptoms was maintained in the 
majority of patients treated with lurasidone, with relatively low rates of relapse, and with minimal effects on weight 
and metabolic parameters.
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Background
Among patients with a diagnosis of bipolar I disorder, 
episodes typically recur over many decades (Suppes et al. 
2000; Marneros and Brieger 2002; Angst et al. 2003) with 
episodes of depression occurring with greater frequency 
than episodes of mania (Judd et  al. 2002; Kupka et  al. 
2007). The persistent risk of recurrent depression and 
the marked degree of depression-related disability have 
led to guideline recommendations that emphasize the 
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importance of maintenance therapy (Grunze et al. 2013; 
Yatham et al. 2013; NICE 2014).
Current guidelines for the maintenance treatment of bipo-
lar disorder recommend lithium, valproate, olanzapine, and 
quetiapine as first-line monotherapies, and combination 
therapy with quetiapine and lithium or valproate as first-
line adjunctive therapies (Yatham et  al. 2013; NICE 2014; 
Grunze et al. 2013; Goodwin et al. 2016). Monotherapy and 
adjunctive therapy with aripiprazole and risperidone long-
acting injection also appear to be effective maintenance 
treatments, but primarily for the prevention of recurrent 
manic episodes, while lamotrigine is recommended primar-
ily for prevention of recurrent depressive episodes.
Among patients in the community receiving long-term 
treatment for bipolar disorder, approximately 50% have 
been reported to experience a recurrence within 2 years 
(Tohen et al. 2003) even when receiving guideline-based 
treatment from clinicians with specialized training in the 
pharmacological management of bipolar disorder (Perlis 
et  al. 2006). Thus, there is clearly a need for additional 
treatment options that are safe, well tolerated, and effec-
tive for the maintenance therapy of bipolar disorder.
Lurasidone, in the dosing range of 20–120  mg/day, has 
been approved in the USA and Canada for the treatment 
of acute bipolar depression, both as monotherapy and as 
adjunctive therapy with lithium or valproate, based on the 
results of 2 positive randomized, double-blind, 6-week tri-
als (Loebel et  al. 2014a, 2014b). In a 6-month, open-label 
extension study (Ketter et  al. 2016), treatment with lur-
asidone was found to be well tolerated and had minimal 
effects on weight, lipids, and measures of glycemic con-
trol. In this open-label extension trial, acute improvement 
in depressive symptoms was maintained during 6 months 
of additional lurasidone therapy, with more than 90% of 
patients who met responder criteria at baseline of the 
extension study continuing to meet responder criteria at 
month 6, and the majority of initial non-responders achiev-
ing responder status by 6 months in both the monotherapy 
group (83%) and in the adjunctive therapy group (73%). 
Furthermore, treatment with lurasidone, without use of 
adjunctive mood stabilizers, was associated with a low rate 
of mania (1.3%) during the 6-month treatment period.
We now report the results of a continuation study in 
which patients who completed the 6-month extension 
study summarized above (Ketter et al. 2016) received up 
to 18 months of additional open-label treatment to evalu-
ate the safety, tolerability, and effectiveness of long-term 
treatment with lurasidone.
Methods
This was an 18-month, open-label, continuation study 
(clinicaltrials.gov identifier: NCT01485640) designed 
to monitor the long-term safety, tolerability, and 
effectiveness of lurasidone in patients who initially met 
DSM-IV-TR criteria for either chronic schizophrenia or 
bipolar I depression. The current analysis is limited to 
the group of patients who participated in this study with 
a bipolar disorder diagnosis; patients with a diagnosis of 
chronic schizophrenia are not included in the current 
report and will be reported separately.
Patients with bipolar depression were initially enrolled 
in one of three 6-week, double-blind, placebo-con-
trolled trials [monotherapy with lurasidone, 1 study; 
clinicaltrials.gov identifier: NCT00868699 (Loebel et  al. 
2014b); adjunctive therapy with lurasidone and lithium 
or valproate, 2 studies; clinicaltrials.gov identifiers: 
NCT00868452 and NCT01284517 (Loebel et  al. 2014a; 
Suppes et  al. 2016)], followed by a 6-month open-label 
extension study of lurasidone in flexible daily doses of 
20–120  mg [clinicaltrials.gov identifier: NCT00868959; 
Ketter et  al. 2016]). Six-month study completers were 
then treated for an additional 18  months with flexible, 
once-daily doses of lurasidone in the range of 20–80 mg. 
Concomitant therapy with mood stabilizers and anti-
depressant medications was permitted throughout the 
open-label studies.
Eligible patients could enroll into this continuation 
study directly after completing the 6-month extension 
study. Patients who had completed the extension study 
prior to the initiation of the current protocol at a study 
site were also permitted to enroll for up to 3 months after 
completion of the prior extension study (N = 34; 27.9% of 
the patients analyzed in the current report).
Patients were included in the current extension study 
if they were judged by the Investigator to be suitable for 
participation in an 18-month, open-label study, able to 
comply with the protocol, and not at imminent risk of 
suicide, or injury to self or others. Patients were excluded 
who answered “yes” to “suicidal ideation” items 4 or 5 on 
the Columbia Suicide Severity Rating Scale (C-SSRS).
The study was conducted from March 2012 to Febru-
ary 2014 at 48 centers in 12 countries in North and South 
America (N =  9), Europe (N =  67), Asia (N =  32), and 
Africa (N  =  14). The study protocol was approved by 
Independent Ethics Committees associated with each 
study center. Prior to entering the current 18-month con-
tinuation study, an informed consent form was reviewed 
and signed by all patients. Study conduct was in accord-
ance with Good Clinical Practices as required by the 
International Conference on Harmonization guidelines 
and in accordance with ethical principles of the dec-
laration of Helsinki of 1975 (as revised in 1983). The 
18-month study was discontinued for administrative rea-
sons on 7 February 2014 by the Sponsor after lurasidone 
became available in the regions in which the study was 
conducted.
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Patients who met entry criteria were treated with flexi-
ble doses of lurasidone in the range of 20–80 mg/day. The 
dose of lurasidone could be adjusted at any time, based 
on the clinical judgment of the Investigator, to optimize 
efficacy and tolerability. Patients were instructed to 
continue the dosing regimen from the previous lurasi-
done extension study (in the evening or morning within 
30 min of eating). At each visit, patients were dispensed 
up to a 3-month supply of study medication, based on 
investigator judgment.
Patients were permitted to be treated concomitantly 
with benzodiazepines, mood stabilizers (e.g., lithium, 
divalproex, or lamotrigine), or antidepressants at the 
discretion of the Investigator. Monoamine oxidase inhib-
itors and antipsychotic medications (other than lurasi-
done) were prohibited.
Safety and effectiveness evaluations
Safety and effectiveness evaluations were performed 
at 3-month intervals, with additional visits scheduled 
if indicated due to adverse events or clinical worsen-
ing. The incidence and severity of treatment-emergent 
adverse events were recorded. Movement disorders 
were assessed using the Barnes Akathisia Rating Scale 
(BARS; Barnes 1989), the Simpson-Angus Scale (SAS; 
Simpson and Angus 1970), and the Abnormal Invol-
untary Movement Scale (AIMS: Guy 1976). Additional 
safety evaluations included weight, vital signs, hema-
tology, chemistries, and urinalysis. Suicidal ideation 
and behavior were assessed using the Columbia Suicide 
Severity Rating Scale (C-SSRS; Posner et  al. 2011). The 
effectiveness of lurasidone was assessed using the Clini-
cal Global Impressions Bipolar Version, Severity of illness 
scale (CGI-BP-S; Spearing et al. 1997) at Baseline of the 
acute double-blind and 6-month extension studies; and 
the Clinical Global Impression, Severity scale was uti-
lized in the current 18-month continuation study (CGI-S; 
Guy 1976). Both scales provide an overall rating of illness 
severity on a 7-point severity scale, with the CGI-BP-S 
providing bipolar-specific prompts.
Statistical analyses
The safety population consisted of all patients who 
received at least one dose of lurasidone in the 18-month 
continuation study that followed the initial 6-week dou-
ble-blind study and the subsequent 6-month open-label 
extension study. The primary safety analyses consisted 
of the incidence of treatment-emergent adverse events, 
serious adverse events, and discontinuations due to 
adverse events. Descriptive statistics were also calculated 
for the following safety variables: body weight, propor-
tion of patients with ≥7% weight change from baseline, 
body mass index (BMI), vital signs, movement disorders 
as assessed by the BARS, SAS, and AIMS scales, as well 
as laboratory results (chemistries, hematology, and uri-
nalysis). Mean (SD) change in the CGI-BP-S and CGI-S 
scores were reported from the baseline of the original 
double-blind acute treatment study based on both an 
observed case (OC) and last observation carried for-
ward to endpoint (LOCF-endpoint) analysis. Treat-
ment response was defined as achieving a CGI-S score 
of  ≤2 (mild severity to no symptoms); remission was 
defined as a CGI-S score = 1 (no symptoms). A post hoc 
Kaplan–Meier survival analysis was performed to esti-
mate probability of relapse during 18  months of open-
label treatment with lurasidone. Relapse was defined as 
meeting one of the following three criteria: (1) a 1-point 
increase over continuation baseline in the CGI-severity 
score; (2) reported adverse event of treatment-emergent 
hypomania, mania, or depression; or (3) discontinuation 
due to treatment-emergent clinical worsening or insuffi-
cient clinical response.
Results
In the three 6-week, double-blind, placebo-controlled 
acute bipolar depression treatment studies combined, 
a total of 941/1199 patients (78.5%) were completers 
(lurasidone, 77.4%; placebo, 80.0%), of whom 817/941 
(86.8%) entered the 6-month extension study, and 
559/817 (68.4%) completed the extension study. A total 
of 122/559 patients (21.8%) provided informed consent 
and entered the current 18-month continuation study, 
of whom 40/122 (32.8%) were completers (Fig. 1). Fifty-
eight of the 82 patients (70.7%) who discontinued from 
the study (out of a total sample of 122) were patients 
who were ongoing at the time the study was terminated 
by the sponsor; all of these patients had received at least 
6  months of treatment prior to study termination. The 
remaining 24 patients discontinued due to adverse event 
(N = 8, 6.6%), insufficient clinical response (N = 2; 1.6%), 
withdrawal of consent (N = 13; 10.7%), and protocol vio-
lation (N = 1; 0.8%).
Baseline demographic and clinical characteristics for 
patients in the current continuation study are summa-
rized in Table  1. Baseline characteristics in the 3 initial 
double-blind, 6 week studies, and the current 18-month 
continuation study were as follows: proportion of males 
(46.7 and 52.5%, respectively), whites (64.0 and 58.2%, 
respectively), use of adjunctive mood stabilizers (58.2 
and 76.2%, respectively), mean age (42.2 and 41.3 years, 
respectively), and age of diagnosis with bipolar disorder 
(28.5 and 31.3 years old, respectively).
Among the 122 patients treated with lurasidone in 
the current study, 93 (76.2%) were receiving adjunctive 
therapy with one of several formulations of valproic acid 
(n  =  58) or lithium (n  =  35). Additional concomitant 
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medications included acetaminophen (12.3%), lorazepam 
(9.0%), zolpidem (6.6%), levothyroxine (4.9%), trihexy-
phenidyl (4.1%), and venlafaxine (4.9%).
The mean (SD) daily dose of lurasidone during the cur-
rent 18-month study was 61.8 (17.5) mg and was similar 
in the monotherapy and adjunctive therapy groups. The 
modal daily dose of lurasidone for the combined therapy 
groups was 20 mg for 9.0% of patients, 40 mg for 11.5% 
of patients, 60  mg for 43.4% of patients, and 80  mg for 
36.1% of patients Table 2.
Safety
During the 18-month continuation phase, at least one 
treatment-emergent adverse event was reported by 
42.6% of patients, with 4.9% of patients rating at least one 
event as “severe.” The most frequent adverse events were 
headache (7.4%); diarrhea, influenza, and nasopharyn-
gitis (4.9% each); depression and vomiting (4.1% each); 
increase in hepatic enzymes, mania, nausea, and viral 
upper respiratory infection (3.3% each); and parkinso-
nian symptoms (2.5%). One patient each (0.8%) reported 
sedation and somnolence. Five patients (4.1%) reported 
extrapyramidal symptoms (Parkinsonism and tremor; no 
patients reported akathisia).
In addition to the 3 patients noted above who discon-
tinued due to treatment-emergent mania or suicidal 
ideation, 5 patients also discontinued due to treatment-
emergent adverse events: 1 patient each due to mania and 
hypomania, 1 patient each due to diabetes and hyper-
glycemia, and 1 patient due to an increase in hepatic 
enzymes.
Six patients experienced a serious adverse event dur-
ing the course of study treatment: one patient with a 
pilonidal cyst, one patient with a fracture of the first and 
second metatarsals, two patients with treatment-emer-
gent symptoms of mania (both were discontinued from 
the study), and two patients with treatment-emergent 
depressive symptoms, one of whom reported suicidal 
ideation and was discontinued from the study. There 
were no deaths in the study. No active suicidal ideation 
was identified on the C-SSRS during the course of the 
study.
Fig. 1 Patient disposition. a Acute phase (6 weeks). b Extension phase (6 months). c Continuation phase (18 months)
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Eighteen months of treatment with lurasidone was 
associated with a mean change, from double-blind base-
line to LOCF-endpoint, of −0.1 on the BARS global 
score, +0.02 on the SAS 10-item mean score, and −0.1 
on the AIMS total score.
The mean weight, at baseline of the 6-week double-
blind trial, in the subgroup of patients (N  =  122) who 
completed the subsequent 6-month extension study 
and entered the 18-month continuation study, was 
75.4  kg, and the mean BMI was 26.6  kg/m2. Among 
patients who completed 24 months of overall treatment 
(N = 55), mean change in weight and BMI was +0.8 kg 
and +0.3 kg/m2, respectively. Among patients who com-
pleted 12 months of treatment in the continuation study 
(N = 118;), mean change in weight and BMI was +1.8 kg 
and +0.7 kg/m2, respectively, with 16.1% having a weight 
gain of ≥7, and 5.9% having a weight loss of ≥7%.
Small median changes from double-blind baseline were 
also observed at months 12 and 24 in metabolic param-
eters and prolactin (Table  3). No clinically significant 
changes were observed for heart rate, orthostatic blood 
pressure (systolic or diastolic), or respiratory rate.
Effectiveness
Improvement in bipolar illness severity observed on lur-
asidone during initial acute and extension phase therapy 
was maintained in the great majority of patients across 
18  months of continuation treatment. At initial double-
blind Baseline, the mean CGI-BP-S score was 4.3. After 
6  weeks of double-blind treatment, the mean CGI-BP-
S score was 2.7 in the lurasidone group and 2.9 in the 
placebo group. After 6  months of extension treatment 
(Baseline of the current continuation study), the mean 
CGI-BP-S score was 2.1. This level of improvement was 
maintained through 18  months of continuation treat-
ment (a minimum of 24 months of total treatment), with 
a mean CGI-Severity score of 2.0 at month 12 (OC), 
1.8 at month 18 (OC), 1.7 at month 24 (OC), and 1.9 at 
LOCF-endpoint.
Across 18  months of continuation treatment, global 
depression symptom severity remained at a low level 
of severity, with 63–81% of patients reporting clini-
cal response, defined as borderline-to-no symptoms 
(CGI-S ≤ 2), and 33–39% reporting full symptom remis-
sion (CGI-S = 1; Fig. 2).
In a post hoc Kaplan–Meier analysis, the estimated 
probability of relapse on lurasidone monotherapy and 
Table 1 Baseline demographic and  clinical characteristics 
of  patient sample at  18-month continuation study base-
line (safety population)
a  In acute double-blind (DB) study
b  Note that the CGI-BP-S scale was used to assess severity at Baseline of the 










History of rapid cycling (≥ 4 episodes in past 
12 months)
7 5.7






Age, years 41.3 12.2
Age at initial bipolar diagnosis, years 31.3 11.8




Acute double-blind baseline 28.8 4.4
6-month extension baseline 13.8 8.7
18-month continuation study baseline 6.5 5.3
CGI-severity scoreb
Acute double-blind baseline 4.3 0.5
6-month extension baseline 2.8 1.0
18-month continuation study baseline 2.1 1.0
Table 2 Change in weight and BMI from double-blind acute phase baseline
Month 12 = 6 months of extension +6 months of maintenance treatment; month 24 = 6 months of extension +18 months of continuation treatment (patients 
randomized to lurasidone in the initial double-blind acute treatment study had an additional 6 weeks of exposure to lurasidone)
BMI body mass index, OC observed case analysis
Baseline N = 122 Mean change (from double-blind acute phase baseline)
6-week double-blind 
mean
6-month extension  
mean
Current study  
mean
Month 12 (OC) Month 24 (OC)
n Mean n Mean
Weight, kg 75.4 75.6 76.3 113 +1.8 55 +0.8
BMI, kg/m2 26.6 26.7 27.0 113 +0.7 55 +0.3
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adjunctive therapy at 6  months was 14.6 and 15.4%, 
respectively; at 12  months, it was 18.3 and 23.4%, 
respectively; and at 18  months, it was 18.3 and 29.1%, 
respectively.
Discussion
This was an 18-month, open-label continuation study 
designed to evaluate the long-term safety and tolerabil-
ity of lurasidone (20–80 mg/day) in patients with bipolar 
depression who had completed 6 weeks of treatment with 
lurasidone or placebo in a randomized, double-blind trial, 
followed by 6 months of open-label extension phase treat-
ment on flexible doses of lurasidone in the dosing range 
of 20–120 mg/day. Concomitant therapy with mood sta-
bilizers was permitted in both open-label studies and in 2 
of the 3 acute double-blind studies. Effectiveness was also 
evaluated as a secondary outcome with a focus on mainte-
nance of effect.
The results of the current study suggest that up to 
2  years of treatment with lurasidone, in the daily dose 
range of 20–80  mg, is associated with a relatively low 
potential for weight gain and adverse metabolic effects. 
Changes in weight, BMI, lipids, glycemic indices, and 
prolactin were small, and not clinically meaningful. 
These long-term data confirm and extend the findings 
obtained in previous long-term trials in schizophre-
nia and bipolar disorder indicating that lurasidone has 
a low propensity for adverse effects on weight, lipids, 
and glucose metabolism (Citrome et  al. 2012; Loebel 
et  al. 2013; Meyer et  al. 2015; Tandon et  al. 2016; Ket-
ter et  al. 2016; Correll et  al.2016). It is well-established 
that bipolar disorder is associated with approximately a 
twofold increased risk of cardiovascular mortality (Osby 
et  al. 2001; Crump et  al. 2013; Miller and Bauer 2014), 
attributable to various factors, including significant 
increased risk of obesity, hyperlipidemia, diabetes, and 
metabolic syndrome (Goldstein et al. 2011; McElroy and 
Keck 2014). Evidence suggests that treatment with many 
widely used atypical antipsychotics is associated with 
adverse cardiometabolic effects that increase mortal-
ity risk (Correll et al. 2015). Lurasidone would appear to 
provide an important long-term treatment option, given 
its low propensity for adverse effects on weight and met-
abolic parameters.
Discontinuation due to adverse events during 
18  months of treatment with lurasidone was relatively 
low (6.6%). Adverse event rates were notably lower than 
rates previously reported for lurasidone during acute 
treatment (Loebel et al. 2014a, b), with only one adverse 
event (headache, 7.4%) occurring with an incidence 
above 5%.
Extrapyramidal symptom-related adverse events were 
reported in a smaller proportion of patients in the cur-
rent study (4.1%) than in previously reported long-term 
treatment studies in schizophrenia (Correll et  al. 2016). 
Consistent with this, use of anticholinergic medication 
was relatively low (4.1%), and minimal effects were noted 
on movement disorder measures.
Overall, the adverse event profile of lurasidone in this 
bipolar population was comparable to what has been 
reported in previous long-term studies of lurasidone in 
patients with schizophrenia (Correll et al. 2016).
Improvement in depressive symptoms was main-
tained on lurasidone in the great majority of patients. 
At baseline of the current study, the mean CGI-Severity 
score was 2.1. The mean CGI-S score remained below 
2 (“borderline mentally ill”) on both OC and LOCF-
endpoint analyses. The proportion of patients reporting 
Table 3 Change in laboratory parameters from double-blind acute phase baseline
Month 12 = 6 months of Extension + 6 months of Maintenance treatment; Month 24 = 6 months of Extension + 18 months of Continuation treatment (patients 
randomized to lurasidone in the initial double-blind acute treatment study had an additional 6 weeks of exposure to lurasidone)
HbA1c glycosylated hemoglobin, LDL low-density lipoprotein, HDL high-density lipoprotein, OC observed case analysis










Month 12 (OC) Month 24 (OC)
n Median n Median
Total cholesterol, mg/dL 195.5 188.7 197.9 111 +5.0 54 −3.0
LDL cholesterol, mg/dL 116.8 110.2 117.5 108 −4.5 53 −10.0
HDL cholesterol, mg/dL 50.5 50.4 50.3 112 1.0 54 −1.0
Triglycerides, mg/dL 151.5 151.0 157.6 111 +10.0 54 +26.0
Glucose, mg/dL 91.1 93.1 93.7 112 +2.5 54 +3.5
HbA1c, % 5.3 5.3 5.4 112 0.0 53 −0.1
Prolactin, ng/mL 10.9 13.1 13.7 112 +0.8 54 +0.6
Prolactin, males 10.1 (N = 64) 9.5 (N = 64) 8.3 (N = 52) 59 −0.2 27 +0.2
Prolactin, females 11.7 (N = 58) 17.3 (N = 57) 19.3 (N = 51) 53 +1.4 27 +0.6
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remission of manic or depressive symptoms during 
18  months of treatment was in the range of 35–38%, 
with remission defined based on stringent CGI-Severity 
criteria (CGI-S = 1) representing the absence of bipolar 
symptomatology.
The results of a Kaplan–Meier analysis found a low 
estimated probability of relapse during 18  months of 
continuation treatment with lurasidone, both as mono-
therapy (18.3%) and adjunctive with lithium or valproate 
(29.1%). These results compare favorably to naturalistic 
studies, with 1.5- to 2-year follow-up, of bipolar patients 
receiving standard maintenance therapy in the commu-
nity, which typically report rates of recurrence of depres-
sion or mania that are in the range of 40–60% (Judd et al. 
2002; Tohen et al. 2003; Joffe et al. 2004; Perlis et al. 2006). 
Double-blind, placebo-controlled recurrence prevention 
trials in bipolar patients also report recurrence rates dur-
ing 1.5–2 years of treatment with atypical antipsychotics 
that were somewhat higher than the current findings, in 
the range of 18–31% (Tohen et al. 2004; Vieta et al. 2008; 
Suppes et al. 2009).
Study limitations
Study limitations included the open-label study design, 
lack of concurrent placebo or other control group, the 
small sample size, and the relatively small proportion 
of patients who completed the study. A total of 71% of 
patients who discontinued prematurely were ongoing in 
the study for at least 6 months, but were discontinued due 
to study termination by the sponsor. Other potential limi-
tations include the use of an enriched sample of patients 
who had demonstrated tolerability and responsivity to lur-
asidone during up to 7.5 months of initial lurasidone ther-
apy, and reliance on relatively minimal efficacy measures.
In summary, up to 2 years of treatment with lurasidone 
(monotherapy or adjunctive therapy) was found to be safe 
and well tolerated in this bipolar I disorder population 
that presented initially with a major depressive episode. 
Consistent with previous long-term trials in patients with 
a diagnosis of schizophrenia, minimal effects on weight 
and metabolic parameters were observed. Improvement 
in depressive symptoms was maintained in the majority 
of patients during long-term lurasidone treatment, with 
relatively low rates of relapse.
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